Items tagged with Drug-resistant TB
TB Alliance and Macleods announce commercial partnership for new therapy for highly drug-resistant TB (post)
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.
Heated debate on access to TB drugs at global meet (post)
A panel discussion on partnership to treat TB at the 50th Union World Conference on Lung Health ended in a heated debate over unavailability and unaffordability of improved TB drugs in India.
50th Union World Conference on Lung Health: Prevention trial targets multidrug-resistant TB (post)
HYDERABAD, INDIA – The National Institute of Allergy and Infectious Diseases is investing $70 million in a phase III clinical trial assessing the use of tuberculosis treatments in preventing multidrug-resistant tuberculosis infection among high-risk individuals, including infected household contacts of MDR-TB patients and people living with HIV, institute officials announced here.
Meeting on update of the WHO drug-resistant TB treatment guidelines (post)
The Guideline Development Group convened a meeting on 12-14 November 2019 on update of the World Health Organization (WHO) drug-resistant TB treatment guidelines.
WHO releases new guidance on treating drug-resistant TB in children and adolescents (post)
WHO/Europe has released an expert opinion on managing drug-resistant tuberculosis (DR-TB) in children and adolescents, supported by a commentary in the Lancet.
New treatment to tackle drug-resistant strains of TB could now be possible (post)
New drugs to treat strains of TB which have become resistant to treatment are now a possibility following a ground breaking discovery from the University of Surrey.
Bedaquiline-based treatment associated with favorable outcomes in patients with MDR-TB (post)
Bedaquiline-based regimens for treating patients with multidrug-resistant tuberculosis, MDR-TB, were associated with favorable outcomes and a lower rate of acquired drug resistance compared with delamanid-based regimens, according to a study conducted in the country of Georgia.
The Stop TB Partnership's Global Drug Facility Pediatric Drug-Resistant TB initiative (post)
The Stop TB Partnership’s Global Drug Facility officially launched the Pediatric Drug-Resistant TB (DR-TB) Initiative aimed at ending the disease by increasing the access of child-friendly DR-TB treatments to children who need them, wherever they are in the world.
RESIST-TB webinar (post)
RESIST-TB will host a webinar on approaches for improving inference from observational multidrug-resistant TB (MDR-TB) treatment cohorts on 27 January 2020.
Webinar: Advocacy for access to DR-TB treatment - webinar materials now available online (post)
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment. The webinar materials are now available online.
Page 62 of 117 · Total posts: 0
←First 61 62 63 Last→